More advanced tumor features (clinical stages II and III, tumor size larger than 2cm, patients with lymph node involvement), as well as HER2 status expression with HER2 2+/FISH+ resulted in a lower pCR rate. This evidence concerns the gene ERBB2 and neoplasm.